Ann: MND Trial Successfully Completes First Patient Cohort, page-110

Yes , would be the NZ side of the ditch https://blindlowvision.org.nz/guide-dogs/

Beauty of being a Trader is being able to drop in and out , so a good chance may be back in here at PAA..PR and Messaging has increased 10 fold.

The last ASX announcement was the most engaging and comprehensive including "Commercial Value" of Scientific Progress and what the MND etc Markets are worth.

4c and Q in 12 days so would think more news flow prior to that.... MPL has provided positive results for nearly 3 years straight... Having the Tablets on hand and manufactured at GMP grade should have added significant value,, but possibly the "Contains impurities" poured cold water over that announcement. ( plus there was not another ASX announcement to state the impurities where additional preservatives , stabilizers etc to clear the negativity from the initial announcement)

If PAA have mastered the ability to deliver MPL and positively effect the mTOR Pathway without the adverse effects of the incumbent two treatments, then with Strategic Messaging the market would certainly jump up and take interest..

Should PAA keep the SP on the current trajectory and keep costs reduced for the next 9 months then the Oppies getting struck would negate the need to for additional funding...

Should hear back today or tomorrow from the DSMB regarding the patient data from cohort 1... Even that delivered well beyond just an ASX announcement should promote additional interest in PAA..

I certainly cant complain at the return garnished from PAA..... NZT

Best of luck to all holders especially the LTH...